TITLE

Vive l'Union! Sanofi/Aventis Likely

AUTHOR(S)
Santini, Laura
PUB. DATE
February 2004
SOURCE
Investment Dealers' Digest;2/2/2004, Vol. 70 Issue 5, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the hostile takeover bid of France-based pharmaceutical company Sanofi-Synthelabo for French-German rival Aventis. Details of the proposed merger offer; Rejection by Aventis of the offer; French government's support for the merger proposal.
ACCESSION #
12132982

 

Related Articles

  • Aventis dismisses merger ideas.  // European Chemical News;1/20/2003, Vol. 78 Issue 2036, p7 

    Reports on the plan of Aventis to consider a merger with Sanofi-Synthélabo. Priority of the company; Factors to be considered for a merger to take place.

  • Aventis board rejects attempt at hostile takeover.  // Inside Tucson Business;3/1/2004, Vol. 13 Issue 35, p9 

    Reports on the resistance of the pharmaceutical firm Aventis SA on the hostile takeover bid by Sanofi-Synthelabo SA in Strasbourg, France. Sales performance of Aventis; Total number of Aventis employees; Recommendation of Aventis to shareholders about the offer.

  • Aventis files second appeal. Beacham, Will // European Chemical News;3/12004, Vol. 80 Issue 2089, p7 

    Reports on the appeal filed by Aventis against the approval of the French stock market regulator Autorité des Marches Financiers (AMF) of the hostile takeover bid of Sanofi-Synthélabo. Amount in cash and shares offered by Sanofi Synthélabo.

  • In the News.  // njbiz;2/2/2004, Vol. 17 Issue 5, p2 

    Presents an update on business in the U.S. as of February 2004. Plans of governors to allocate lots for slot machines in Pennsylvania; Decision of Aventis to reject a takeover bid by Sanofi-Synthelabo; Hearings on a bill which would revive the office of the state environmental prosecutor.

  • Merger of drug firms to create behemoth.  // Drug Topics;5/17/2004, Vol. 148 Issue 10, p8 

    Reports that the Sanofi-Aventis would be the new name of the combined Aventis and Sanofi-Synthelabo merger.

  • News Tip: Mergers Such As Sanofi-Aventis May Actually Create Room for New Players in Pharmaceutical Market, Duke Professor Says.  // Ascribe Newswire: Medicine;4/27/2004, p103 

    Mergers like Monday's deal between pharmaceutical companies Sanofi-Synthelabo SA and Aventis SA may actually create room for the growth of smaller companies, a Duke University business professor says. Mergers have become a tool for survival among large pharmaceutical companies focused on the...

  • Sanofi, Aventisto merge comms ops. Herskovits, Beth // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p12 

    Reports on the possible merger of communication departments of Sanofi-Synthelabo SA and Aventis SA. Responsibility of Nicole Cranois, member of management committee made up of PR executives of each pharmaceutical company; Refusal of Joelle Sissmann to discuss whether the merger would eliminate...

  • Sanofi takeover jeopardizes Aventis biotech deals. Mitchell, Peter // Nature Biotechnology;Jun2004, Vol. 22 Issue 6, p639 

    On April 25, Sanofi-Synthelabo SA secured its takeover of rival pharmaceutical giant Aventis SA. The deal is expected to negatively affect many of the 200 or so R&D collaborations that Aventis has set up with biotech companies, given that Sanofi prefers in-house R&D to such collaborations....

  • Another European Giant Emerges. S.H. // Pharmaceutical Executive;Jun2004, Vol. 24 Issue 6, p28 

    Reports on developments in mergers and acquisitions in the pharmaceutical industry. Sanofi-Synthelabo SA's acquisition of Aventis to form the entity, Sanofi-Aventis, which will become the world's third largest pharmaceutical company; Worth of the deal; Advantage and disadvantage of mergers;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics